AAAAAA

   
Results: 1-23 |
Results: 23
Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption
Authors: Violette, SM Guan, W Bartlett, C Smith, JA Bardelay, C Antoine, E Rickles, RJ Mandine, E Van Schravendijk, MR Adams, SE Lynch, BA Shakespeare, WC Yang, M Jacobsen, VA Takeuchi, CS Macek, KJ Bohacek, RS Dalgarno, DC Weigele, M Lesuisse, D Sawyer, TK Baron, R
Citation: Sm. Violette et al., Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption, BONE, 28(1), 2001, pp. 54-64
Familial aggregation in specific language impairment
Authors: Tallal, P Hirsch, LS Realpe-Bonilla, T Miller, S Brzustowicz, LM Bartlett, C Flax, JF
Citation: P. Tallal et al., Familial aggregation in specific language impairment, J SPEECH L, 44(5), 2001, pp. 1172-1182
A novel phosphotyrosine mimetic 4 '-carboxymethyloxy-3 '-phosphonophenylalanine (Cpp): Exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain
Authors: Kawahata, N Yang, MG Luke, GP Shakespeare, WC Sundaramoorthi, R Wang, YH Johnson, D Merry, T Violette, S Guan, W Bartlett, C Smith, J Hatada, M Lu, XD Dalgarno, DC Eyermann, CJ Bohacek, RS Sawyer, TK
Citation: N. Kawahata et al., A novel phosphotyrosine mimetic 4 '-carboxymethyloxy-3 '-phosphonophenylalanine (Cpp): Exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain, BIOORG MED, 11(17), 2001, pp. 2319-2323
Are randomised controlled trials in the BMJ different?
Authors: Egger, M Bartlett, C Juni, P
Citation: M. Egger et al., Are randomised controlled trials in the BMJ different?, BR MED J, 323(7323), 2001, pp. 1253-1254
Intravenous iron for CAPD populations: proactive or reactive strategies?
Authors: Richardson, D Bartlett, C Jolly, H Will, EJ
Citation: D. Richardson et al., Intravenous iron for CAPD populations: proactive or reactive strategies?, NEPH DIAL T, 16(1), 2001, pp. 115-119
Optimizing erythropoietin therapy in hemodialysis patients
Authors: Richardson, D Bartlett, C Will, EJ
Citation: D. Richardson et al., Optimizing erythropoietin therapy in hemodialysis patients, AM J KIDNEY, 38(1), 2001, pp. 109-117
Value of flow diagrams in reports of randomized controlled trials
Authors: Egger, M Juni, P Bartlett, C
Citation: M. Egger et al., Value of flow diagrams in reports of randomized controlled trials, J AM MED A, 285(15), 2001, pp. 1996-1999
Dietary sodium and blood pressure.
Authors: Bartlett, C Hooper, L Ebrahim, S
Citation: C. Bartlett et al., Dietary sodium and blood pressure., N ENG J MED, 344(22), 2001, pp. 1717-1718
Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain
Authors: Metcalf, CA Eyermann, CJ Bohacek, RS Haraldson, CA Varkhedkar, VM Lynch, BA Bartlett, C Violette, SM Sawyer, TK
Citation: Ca. Metcalf et al., Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain, J COMB CHEM, 2(4), 2000, pp. 305-313
A Src SH2 selective binding compound inhibits osteoclast-mediated resorption
Authors: Violette, SM Shakespeare, WC Bartlett, C Guan, W Smith, JA Rickles, RJ Bohacek, RS Holt, DA Baron, R Sawyer, TK
Citation: Sm. Violette et al., A Src SH2 selective binding compound inhibits osteoclast-mediated resorption, CHEM BIOL, 7(3), 2000, pp. 225-235
Intervention thresholds and ceilings can determine the haemoglobin outcomedistribution in a haemodialysis population
Authors: Richardson, D Bartlett, C Will, EJ
Citation: D. Richardson et al., Intervention thresholds and ceilings can determine the haemoglobin outcomedistribution in a haemodialysis population, NEPH DIAL T, 15(12), 2000, pp. 2007-2013
Rich or plain?
Authors: Bartlett, C
Citation: C. Bartlett, Rich or plain?, NEW SCI, 167(2245), 2000, pp. 49-49
Natural attenuation of chlorinated ethene compounds: model development andfield-scale application at the Dover site
Authors: Clement, TP Johnson, CD Sun, YW Klecka, GM Bartlett, C
Citation: Tp. Clement et al., Natural attenuation of chlorinated ethene compounds: model development andfield-scale application at the Dover site, J CONTAM HY, 42(2-4), 2000, pp. 113-140
Structure-based design of an osteoclast-selective, nonpeptide Src homology2 inhibitor with in vivo antiresorptive activity
Authors: Shakespeare, W Yang, M Bohacek, R Cerasoli, F Stebbins, K Sundaramoorthi, R Azimioara, M Vu, C Pradeepan, S Metcalf, C Haraldson, C Merry, T Dalgarno, D Narula, S Hatada, M Lu, XD van Schravendijk, MR Adams, S Violette, S Smith, J Guan, W Bartlett, C Herson, J Iuliucci, J Weigele, M Sawyer, T
Citation: W. Shakespeare et al., Structure-based design of an osteoclast-selective, nonpeptide Src homology2 inhibitor with in vivo antiresorptive activity, P NAS US, 97(17), 2000, pp. 9373-9378
Structure-based design of novel bicyclic nonpeptide inhibitors for the SrcSH2 domain
Authors: Shakespeare, WC Bohacek, RS Azimioara, MD Macek, KJ Luke, GP Dalgarno, DC Hatada, MH Lu, XD Violette, SM Bartlett, C Sawyer, TK
Citation: Wc. Shakespeare et al., Structure-based design of novel bicyclic nonpeptide inhibitors for the SrcSH2 domain, J MED CHEM, 43(21), 2000, pp. 3815-3819
Can trace element distributions in migmatites be used as analogues in understanding petrogenesis of anatectic granites
Authors: Nabelek, PI Bartlett, C Glascock, M
Citation: Pi. Nabelek et al., Can trace element distributions in migmatites be used as analogues in understanding petrogenesis of anatectic granites, PHYS CH P A, 24(3), 1999, pp. 295-298
Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70
Authors: Vu, CB Corpuz, EG Pradeepan, SG Violette, S Bartlett, C Sawyer, TK
Citation: Cb. Vu et al., Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70, BIOORG MED, 9(20), 1999, pp. 3009-3014
An international outbreak of Vero cytotoxin-producing Escherichia coli O157 infection amongst tourists; a challenge for the European infectious disease surveillance network
Authors: Pebody, RG Furtado, C Rojas, A McCarthy, N Nylen, G Ruutu, P Leino, T Chalmers, R de Jong, B Donnelly, M Fisher, I Gilham, C Graverson, L Cheasty, T Willshaw, G Navarro, M Salmon, R Leinikki, P Wall, P Bartlett, C
Citation: Rg. Pebody et al., An international outbreak of Vero cytotoxin-producing Escherichia coli O157 infection amongst tourists; a challenge for the European infectious disease surveillance network, EPIDEM INFE, 123(2), 1999, pp. 217-223
Markers of inappropriate placement in acute psychiatric inpatient care: a five hospital study
Authors: Bartlett, C Evans, M Holloway, J O'Connor, S Harrison, G
Citation: C. Bartlett et al., Markers of inappropriate placement in acute psychiatric inpatient care: a five hospital study, SOC PSY PSY, 34(7), 1999, pp. 367-375
Erythropoietin resistance due to dialysate chloramine: the two-way trafficof solutes in haemodialysis
Authors: Richardson, D Bartlett, C Goutcher, E Jones, CH Davison, AM Will, EJ
Citation: D. Richardson et al., Erythropoietin resistance due to dialysate chloramine: the two-way trafficof solutes in haemodialysis, NEPH DIAL T, 14(11), 1999, pp. 2625-2627
Outcome-based medication programs
Authors: Will, EJ Bartlett, C
Citation: Ej. Will et C. Bartlett, Outcome-based medication programs, DIALYSIS T, 28(2), 1999, pp. 58
Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70
Authors: Vu, CB Corpuz, EG Merry, TJ Pradeepan, SG Bartlett, C Bohacek, RS Botfield, MC Eyermann, CJ Lynch, BA MacNeil, IA Ram, MK van Schravendijk, MR Violette, S Sawyer, TK
Citation: Cb. Vu et al., Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, J MED CHEM, 42(20), 1999, pp. 4088-4098
Trauma admissions in the elderly: how does a patient's age affect the likelihood of their being admitted to hospital after a fracture?
Authors: Johansen, A Evans, R Bartlett, C Stone, M
Citation: A. Johansen et al., Trauma admissions in the elderly: how does a patient's age affect the likelihood of their being admitted to hospital after a fracture?, INJURY, 29(10), 1998, pp. 779-784
Risultati: 1-23 |